Oculus Innovative Sciences Receives FDA Clearance for Over-the-Counter Marketing of Dermacyn(TM) Wound Care (Business Wire via Yahoo! Finance)
PETALUMA, Calif.----March 8, 2006--Hoji Alimi, president and CEO of Oculus Innovative Sciences, today announced that the U.S. Food and Drug Administration has granted clearance to market a consumer-specific version of Dermacyn Wound Care as an over-the-counter product in the United States.